Fast Five Quiz: Relapsed/Refractory Marginal Zone Lymphoma

Christina Poh, MD


November 03, 2021

Figure 1. Light micrograph of splenic marginal zone lymphoma.

Patients with symptomatic splenic MZL (as evidenced by splenomegaly or cytopenias) and without hepatitis C infection should undergo a trial of rituximab prior to the consideration of splenomegaly. Approximately 20% of splenic MZL is associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, cold agglutinin disease, and acquired von Willebrand disease.

Learn more about splenic MZL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.